GENENTECH ADDS WARNINGS TO AVASTIN

Genentech Inc. has added warnings about a rare brain condition called reversible posterior leukoencephalopathy syndrome, or RPLS, in patients using its cancer drug Avastin, the Food and Drug Administration said.

Los Angeles Times (http://www.latimes.com/business/la-fi-briefs26.4sep26,1,6167245.story?coll=la-headlines-business)